A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)

Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
10/2004
10/14/2004	WO2004087188A1 Histamine binding compounds for treatment method for disease conditions mediated by neutrophils
10/14/2004	WO2004087178A1 A formulation comprising a bacterial strain
10/14/2004	WO2004087173A2 Formulations for mediating inflammation and for reducing blood cholesterol
10/14/2004	WO2004087158A2 Muscarinic m1 receptor agonists for pain management
10/14/2004	WO2004087142A1 Quinoline-2-one-derivatives for the treatment of airways diseases
10/14/2004	WO2004087119A2 Compositions containing superoxide dismutase and a selected et 5-lipoxygenase inhibitor and uses thereof
10/14/2004	WO2004087074A2 Process for making substituted pyrazoles
10/14/2004	WO2004071392A8 Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4)
10/14/2004	WO2004069256A8 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
10/14/2004	WO2004042402A3 Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
10/14/2004	WO2004042076A3 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4a (pde4a)
10/14/2004	WO2004032840A3 Compounds, compositions, and methods
10/14/2004	WO2004016769A3 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
10/14/2004	WO2004000781A3 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
10/14/2004	WO2003065985A3 Uses of mammalian cytokine; related reagents
10/14/2004	WO2003031475A8 Antibodies against kdr, their production and uses
10/14/2004	US20040204599 an end-terminal group, which is isopropyl, sec.-butyl, or tert.-butyl group; a leading group; and a long-chain aliphatic, non-cyclic, saturated or unsaturated, hydrocarbon group that links end-terminal group and leading group; for cancer therapy, prevention, and immune boosting and inflammation functions
10/14/2004	US20040204586 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
10/14/2004	US20040204568 Comprises nucleotide sequences coding cell adhesion molecules for use in the diagnosis, prevention and treatment of autoimmune and cell proliferative disorders
10/14/2004	US20040204494 Having anticancer, anti-proliferous and anti-inflammatory effects and immunosuppressive and muscle relaxing functions
10/14/2004	US20040204488 S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate crystalline salt
10/14/2004	US20040204467 Use of 5HT3-receptor-antagonists
10/14/2004	US20040204465 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
10/14/2004	US20040204464 Isoxazoline compounds having MIF antagonist activity
10/14/2004	US20040204452 to decompose peroxynitrite anion into harmless nitrate or nitrite endproducts which prevents the free radical-mediated cell damage; cytoprotective; Alzheimer's disease; 3,5-dimethylisoxazole-4-sulfonic acid 4-pyrrolidin-1-ylphenylamide
10/14/2004	US20040204437 Substituted arylamine derivatives and methods of use
10/14/2004	US20040204436 Imidazonaphthyridines
10/14/2004	US20040204418 For prophylaxis and therapy of asthma, chronic obstructive pulmonary disease, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilia, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease
10/14/2004	US20040204417 For therapy of cancer
10/14/2004	US20040204413 Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
10/14/2004	US20040204411 Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
10/14/2004	US20040204408 Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
10/14/2004	US20040204392 use of trilostane or a 3-enol C1-4 alkanoate ester thereof; treatment of Cushing's syndrome in humans and veterinary animals
10/14/2004	US20040204391 Applying onto healed wound a composition comprising a fluid, film-forming carrier, and subsequently hardening the carrier into a tangible membrane juxtaposed to the healed wound thereby reducing scarring or improving the appearance thereof
10/14/2004	US20040204368 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
10/14/2004	US20040204355 alpha 7 receptor is the alpha -bungarotoxin sensitive receptor that influences the release of proinflammatory cytokines from macrophages
10/14/2004	US20040204345 Using recombinant zinc finger proteins; use in human therapeutic applications such as cancer therapy and altering plant phenotypes, including disease resistance, fruit ripening
10/14/2004	US20040203144 Using calcium-activated chloride channels (CLCA) to identify modulators for treatment of bronchitis, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD) and bronchiectasis
10/14/2004	US20040203105 for drug screening emzyme inhibitors using genetically engineered animal models; for anticancer agents
10/14/2004	US20040203104 for drug screening enzyme inhibitors; genetic engineering; comprising subjecting the sample to a polymerase chain reaction, a northern hybridization assay or an in situ hybridization assay
10/14/2004	US20040203099 Conjugate of a transport protein and a protein for modulation of notch signalling
10/14/2004	US20040203098 Compounds and methods for modulating activation of NF-kappaB
10/14/2004	US20040203014 Neurotransmisson-associated proteins
10/14/2004	US20040202702 Method and composition for the treatment of scars
10/14/2004	US20040202671 helminths obtained from preparatory animals raised in a specific human pathogen-free environment used to treat an excessive immune response including an aberrant/enhanced Th1 response, e.g., Crohn's disease and ulcerative colitis
10/14/2004	US20040202650 Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies
10/14/2004	US20040202624 Galenical formulation
10/14/2004	US20040202617 Delivery of opioids through an inhalation route
10/14/2004	DE10313446A1 Phenazon-haltiges Migränemedikament Phenazone-containing migraine medication
10/14/2004	CA2523126A1 Thiazoles useful as inhibitors of protein kinases
10/14/2004	CA2523125A1 Thiazoles useful as inhibitors of protein kinases
10/14/2004	CA2521052A1 Nitric oxide in treatment of inflammation
10/14/2004	CA2520724A1 Benzopyran compounds useful for treating inflammatory conditions
10/14/2004	CA2520674A1 Process for making substituted pyrazoles
10/14/2004	CA2520580A1 Histamine binding compounds for treatment method for disease conditions mediated by neutrophils
10/14/2004	CA2520125A1 Muscarinic m1 receptor agonists for pain management
10/14/2004	CA2519291A1 Chromene derivatives as anti-inflammatory agents
10/13/2004	EP1466914A1 Amorphous substance of tricyclic triazolobenzazepine derivative
10/13/2004	EP1466913A1 Benzoylecgonine, ecgonine and ecgonidine derivatives
10/13/2004	EP1466906A1 Heterocyclic urea and related compounds useful as anti-inflammatory agents
10/13/2004	EP1466904A1 Biaryl compound and use thereof
10/13/2004	EP1466899A1 Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
10/13/2004	EP1466891A1 Carboxylic acid derivative
10/13/2004	EP1466615A1 Pharmaceutical composition
10/13/2004	EP1466613A1 Compositions for mucosal and oral administration comprising hCG fragments
10/13/2004	EP1466612A1 Treatment of inflammation and sepsis with hCG derived peptides
10/13/2004	EP1466605A2 Calcium channel blockers
10/13/2004	EP1466598A2 PDE-IV inhibitors
10/13/2004	EP1466591A1 Cosmetic or dermatological composition obtained by lyophilisation of biotechnological polysaccharides and marine active compounds
10/13/2004	EP1465996A2 Raf/ras binding compounds
10/13/2004	EP1465924A2 Modulators of notch ic protease activity for use in immunotherapy
10/13/2004	EP1465916A2 Novel g proein-coupled receptor, gave7
10/13/2004	EP1465891A2 Inhibitors of dipeptidyl peptidase iv
10/13/2004	EP1465889A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
10/13/2004	EP1465886A1 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
10/13/2004	EP1465880A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
10/13/2004	EP1465877A1 Positive-working photoimageable bottom antireflective coating
10/13/2004	EP1465869A1 Modulators of lxr
10/13/2004	EP1465854A2 Chalcone derivatives and their use to treat diseases
10/13/2004	EP1465663A1 Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
10/13/2004	EP1465649A2 Methods and compositions for derepression of iap-inhibited caspase
10/13/2004	EP1465636A2 Compositions and methods for enhancing corticosteriod delivery
10/13/2004	EP1465630A1 Cyclic urea derivatives with 5-ht2c receptor activity
10/13/2004	EP1465623A1 Urea derivatives
10/13/2004	EP1465622A1 Use of ppar activators for the treatment of pulmonary fibrosis
10/13/2004	EP1465619A1 Suppression of cartilage degradation via the estrogen receptor
10/13/2004	EP1465616A1 Treatment of statin side effects using uridine derivatives
10/13/2004	EP1465614A2 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
10/13/2004	EP1465596A1 Polymeric gel system for the controlled delivery of codrugs
10/13/2004	EP1465593A1 Solid orally-dispersible pharmaceutical formulation
10/13/2004	EP1465577A2 Methods for improving the aesthetic appearance of skin
10/13/2004	EP1397137A4 Hydantion derivatives as inhibitors of matrix metalloproteinases
10/13/2004	EP1322309A4 High affinity small molecule c5a receptor modulators
10/13/2004	EP1280820B1 Anti-inflammatory compounds and uses thereof
10/13/2004	EP1280797B1 Inhibitors of dipeptidyl peptidase iv
10/13/2004	EP1268472B1 3-aminopyrazole inhibitors of cyclin dependent kinases
10/13/2004	EP1207866B1 Delayed-action form of administration containing tramadol saccharinate
10/13/2004	EP1202628B1 Novel hypoxanthine and thiohypoxanthine compounds
10/13/2004	EP1200151B1 Drug delivery device for insertion into the vagina, rectum or nasal cavity
10/13/2004	EP1169038A4 Cyclic protein tyrosine kinase inhibitors

1 ... 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 ... 1272